Compositions for affecting weight loss

Details Compositions for affecting weight loss Compositions for affecting weight loss

2006-02-17

2008-12-09

Krass, Frederick (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S649000, C514S909000, C514S964000, C424S457000, C424S468000

Reexamination Certificate

active

07462626

ABSTRACT:
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

REFERENCES:
patent: 3819706 (1974-06-01), Mehta
patent: 3885046 (1975-05-01), Mehta
patent: 4089855 (1978-05-01), Chatterjie et al.
patent: 4172896 (1979-10-01), Uno et al.
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4689332 (1987-08-01), McLaughlin et al.
patent: 4831031 (1989-05-01), Lowe, III et al.
patent: 5312925 (1994-05-01), Allen et al.
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5403595 (1995-04-01), Kitchell et al.
patent: 5426112 (1995-06-01), Zagon et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5486362 (1996-01-01), Kitchell et al.
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5763493 (1998-06-01), Ruff et al.
patent: 5817665 (1998-10-01), Dante
patent: 5856332 (1999-01-01), Dante
patent: 5958962 (1999-09-01), Cook
patent: 6004970 (1999-12-01), O'Malley et al.
patent: 6034091 (2000-03-01), Dante
patent: 6048322 (2000-04-01), Kushida
patent: 6071537 (2000-06-01), Shank
patent: 6071918 (2000-06-01), Cook
patent: 6110973 (2000-08-01), Young
patent: 6150366 (2000-11-01), Arenson et al.
patent: 6191117 (2001-02-01), Kozachuk
patent: 6197827 (2001-03-01), Cary
patent: 6210716 (2001-04-01), Chen et al.
patent: 6245766 (2001-06-01), Watsky
patent: 6248363 (2001-06-01), Patel et al.
patent: 6262049 (2001-07-01), Coffin et al.
patent: 6274579 (2001-08-01), Morgan et al.
patent: 6323236 (2001-11-01), McElroy
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6437147 (2002-08-01), Anderson et al.
patent: 6441038 (2002-08-01), Loder et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6541478 (2003-04-01), O'Malley et al.
patent: 6548551 (2003-04-01), Hinz
patent: 6569449 (2003-05-01), Stinchcomb et al.
patent: 6589553 (2003-07-01), Li et al.
patent: 6686337 (2004-02-01), Connor
patent: 6713488 (2004-03-01), Sadée et al.
patent: 6905708 (2005-06-01), Li et al.
patent: 7109198 (2006-09-01), Gadde et al.
patent: 2001/0025038 (2001-09-01), Coffin et al.
patent: 2002/0025972 (2002-02-01), Hintz
patent: 2002/0037836 (2002-03-01), Henriksen
patent: 2002/0090615 (2002-07-01), Rosen et al.
patent: 2002/0198227 (2002-12-01), Bernstein
patent: 2003/0055008 (2003-03-01), Marcotte
patent: 2003/0130322 (2003-07-01), Howard
patent: 2003/0144174 (2003-07-01), Brenna et al.
patent: 2003/0144271 (2003-07-01), Shulman
patent: 2004/0002462 (2004-01-01), Najarian
patent: 2004/0029941 (2004-02-01), Jennings
patent: 2004/0033965 (2004-02-01), Gadde et al.
patent: 2004/0106576 (2004-06-01), Jerussi et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0158194 (2004-08-01), Wolff et al.
patent: 2004/0198668 (2004-10-01), Gadde et al.
patent: 2004/0204472 (2004-10-01), Briggs et al.
patent: 2004/0242974 (2004-12-01), Glover
patent: 2004/0254208 (2004-12-01), Weber et al.
patent: 2005/0004106 (2005-01-01), Romano
patent: 2005/0026986 (2005-02-01), Maruani et al.
patent: 2005/0137144 (2005-06-01), Gadde et al.
patent: 2005/0143322 (2005-06-01), Gadde et al.
patent: 2005/0154002 (2005-07-01), Crooks et al.
patent: 2005/0181070 (2005-08-01), Gadde et al.
patent: 2005/0215552 (2005-09-01), Gadde et al.
patent: 2005/0277579 (2005-12-01), Krishnano et al.
patent: 2006/0009514 (2006-01-01), Gadde et al.
patent: 2006/0058293 (2006-03-01), Weber et al.
patent: 2006/0079501 (2006-04-01), Gadde et al.
patent: 2006/0100205 (2006-05-01), Weber et al.
patent: 2006/0122127 (2006-06-01), Rao et al.
patent: 2006/0142290 (2006-06-01), Weber et al.
patent: 2006/0160750 (2006-07-01), Gadde et al.
patent: 2006/0276412 (2006-12-01), Tollefson
patent: 0 442 769 (1991-08-01), None
patent: WO 94/20100 (1994-09-01), None
patent: WO 96/09047 (1996-03-01), None
patent: WO 99/37305 (1999-07-01), None
patent: WO 00/51546 (2000-09-01), None
patent: WO 00/76493 (2000-12-01), None
patent: WO 01/62257 (2001-08-01), None
patent: WO 03/013524 (2003-02-01), None
patent: WO 03/092682 (2003-11-01), None
patent: WO 03/097046 (2003-11-01), None
patent: WO 03/097046 (2003-11-01), None
patent: WO 2004/009015 (2004-01-01), None
patent: WO 2004/050020 (2004-06-01), None
patent: WO 2004/050020 (2004-06-01), None
patent: WO 2004/096201 (2004-11-01), None
patent: WO 2004/110368 (2004-12-01), None
patent: WO2004/110375 (2004-12-01), None
patent: WO 2005/000217 (2005-01-01), None
patent: WO 2005/049043 (2005-06-01), None
patent: WO 2006/017504 (2006-02-01), None
“A Novel Twist on Binge Eating Treatment” Primary Psychiatry; 6(10) 24-29 (1999).
Altman and Bland. “Standard Deviations and Standard Errors,” BMJ; 2005:331:903.
Appolinario et al. “Pharmacological Approaches in the Treatment of Binge Eating Disorder.” Current Drug Targets; 5:301-307 (2004).
Asconape. “Some Common Issues in the Use of Antiepileptic Drugs.” Seminars in Neurology; 22(1):27-39 (2002).
Atkinson, Clinical Guidelines on the identification, Evaluation, and pharamacologic treatment of obesity in Adults, Online, Jul. 25, 2003, URL:http://www.endotext.org.obesity/obesity15b/obesity15b.htm.
Ayala, “Weight Loss Associated With the Administration of Zonisamide”, AES Proceedings, Epilepsia 41(Suppl. 7) :99 (2000) -No. 2.041.
Ayala et al, “Weight Loss Associated With the Administration of Zonisamide”, A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, Dec. 1-6, 2000, Los Angeles, California.
Beelen, et al. “Asymptomatic QTC prolongation associated with queitiapine fumarate overdose in a patient being treated with risperidone” Human & Experimental Toxicology 92001) 20, 215-219.
Calabrese, et al. Letters to the Editors, “Lamotrigine and Clozapine for Bipolar Disorder” American J. of Psychiatry, vol. 157 Sep. 9, 2000, 1523.
Carlsen, et al. “Evidence for dissociation of insulin-and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease” Diabetes Research and Clinical Practice Amersterdam, vol. 39, No. 1, Jan. 1998, pp. 47-54.
Carroll, F.I. J. Med. Chem , 46:10 (2003).
Chen, et al. “Synergistic Effects of Cannabiniod inverse agonist AM251 and opiod antagonist namefene on food intake” Brain Res. vol. 999, Jan. 2004, pp. 22-230.
Cone, et al. “The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis,”Int'l Journal of Obesity, 25(5):S63-S67 (2001).
Dechant et al. Drugs, 41:225-253 (1991).
Dembowski, et al. “Successful Antimanic Treatment and Mood Stabilization with Lamotrigine, Clozapine, and Valproate in a Bipolar Patient after Lithium-induced Cerebellar Deterioration” Letter Pharmacopsychiatry, 2003; 36 83-86.
Devlin, et al. Int. J. Eating Disord. 28:325-332 (2000).
Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision, p. 583-595 (2000).
Dursen, et al., Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia, Arch Gen Psychiatry vol. 56, Oct. 1999, 950-951.
Dursun, et al. “Lamotrgine-Clozapine Combination in Refractory Schizophrenia: Three Cases” J. Neuropsychiatry Clin. Neuroscience, 14:1, Winter 2002, 86.
Dursun, et al. “Augmenting Antipsychotic treatment with Lamotrigine or topiramate in patients with treatment-resistant Schizophrenia: a naturalist

Affiliated with

Also associated with

Rating

Compositions for affecting weight loss does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for affecting weight loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for affecting weight loss will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4047768